HALOPERIDOL DECANOATE IN CHRONIC-SCHIZOPHRENIA - A STUDY OF 12 MONTHS WITH PLASMA-LEVELS

被引：13

作者：

ALTAMURA, CA ^{[1
]}

COLACURCIO, F ^{[1
]}

MAURI, MC ^{[1
]}

MORO, AR ^{[1
]}

DENOVELLIS, F ^{[1
]}

机构：

[1] UNIV MILAN,DEPT CLIN PSYCHIAT,CLIN NEUROPSYCHOPHARMACOL LAB,I-20122 MILAN,ITALY

来源：

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | 1990年 / 14卷 / 01期

关键词：

C; catatonic; D; DG; diagnosis; disorganized; EPSE; extrapyramidal side-effects rating scale; haioperidol decanoate; haloperidol; haloperidol decanoate; HL; HL-D; L/D; level/dose ratio; not performed; NP; P; paranoid; patient; pharmacokinetics; PL; plasma levels; PT; schizophrenia; SD; standard deviation; U; undifferentiated; years; yrs;

D O I：

10.1016/0278-5846(90)90061-K

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

1. 1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50-300 mg i.m. monthly dose) for 12 months. 2. 2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population. 3. 3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p < 0.01) higher EPSE total scores compared to those with a duration of illness < 10 yrs (Group 1). 4. 4. A positive correlation was found between the administered dose and haloperidol plasma levels. 5. 5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1. 6. 6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses. © 1990.

引用

页码：25 / 35

页数：11

共 21 条

[1] HALOPERIDOL DETERMINATION IN SERUM AND CEREBROSPINAL-FLUID USING GAS-LIQUID-CHROMATOGRAPHY WITH NITROGEN PHOSPHORUS DETECTION - APPLICATION TO PHARMACOKINETIC STUDIES [J].

ABERNETHY, DR ;

GREENBLATT, DJ ;

OCHS, HR ;

WILLIS, CR ;

MILLER, DD ;

SHADER, RI .

JOURNAL OF CHROMATOGRAPHY, 1984, 307 (01) :194-199

[2] EARLY UNWANTED EFFECTS OF FLUPHENAZINE ESTERS RELATED TO PLASMA FLUPHENAZINE CONCENTRATIONS IN SCHIZOPHRENIC-PATIENTS [J].

ALTAMURA, AC ;

CURRY, SH ;

MONTGOMERY, S ;

WILES, DH .

PSYCHOPHARMACOLOGY, 1985, 87 (01) :30-33

[3]

ALTAMURA AC, 1989, IN PRESS PHARMACOPSY

[4] HALOPERIDOL DECANOATE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN PSYCHOSIS [J].

BERESFORD, R ;

WARD, A .

DRUGS, 1987, 33 (01) :31-49

[5] PHARMACOKINETICS OF HALOPERIDOL IN PSYCHOTIC-PATIENTS [J].

CHENG, YF ;

PAALZOW, LK ;

BONDESSON, U ;

EKBLOM, B ;

ERIKSSON, K ;

ERIKSSON, SO ;

LINDBERG, A ;

LINDSTROM, L .

PSYCHOPHARMACOLOGY, 1987, 91 (04) :410-414

[6] INTRAMUSCULAR HALOPERIDOL DECANOATE FOR NEUROLEPTIC MAINTENANCE THERAPY - EFFICACY, DOSAGE SCHEDULE AND PLASMA-LEVELS - AN OPEN MULTI-CENTER STUDY [J].

DEBERDT, R ;

ELENS, P ;

BERGHMANS, W ;

HEYKANTS, J ;

WOESTENBORGHS, R ;

DRIESENS, F ;

REYNTJENS, A ;

VANWIJNGAARDEN, I .

ACTA PSYCHIATRICA SCANDINAVICA, 1980, 62 (04) :356-363

[7] THEORETICAL AND PRACTICAL IMPORTANCE OF PLASMA-LEVELS OF HALOPERIDOL - CORRELATIONS WITH CLINICAL AND COMPUTERIZED EEG DATA [J].

DEBUCK, RP ;

ZELASCHI, N ;

GILLES, C ;

DURDU, J ;

BRAUMAN, H .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY, 1981, 5 (5-6) :499-502

[8] PHARMACOKINETICS AND THERAPEUTIC EFFICACY OF HALOPERIDOL DECANOATE AFTER LOADING DOSE ADMINISTRATION [J].

DECUYPER, H ;

BOLLEN, J ;

VANPRAAG, HM ;

VERSTRAETEN, D .

BRITISH JOURNAL OF PSYCHIATRY, 1986, 148 :560-566

[9]

FORSMAN A, 1976, CURR THER RES CLIN E, V20, P319

[10] CLINICAL-RESPONSE AND PLASMA HALOPERIDOL LEVELS IN SCHIZOPHRENIA [J].

MAVROIDIS, ML ;

KANTER, DR ;

HIRSCHOWITZ, J ;

GARVER, DL .

PSYCHOPHARMACOLOGY, 1983, 81 (04) :354-356

← 1 2 3 →